Patents Examined by Padmashri Ponnaluri
  • Patent number: 7173005
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: February 6, 2007
    Assignees: Antyra Inc., Novo Nordisk A/S
    Inventors: Renuka Pillutla, Olga Dedova, Arthur J. Blume, Neil I. Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-Chuan Hsiao, Michael Lennick, Paul Fletcher
  • Patent number: RE39545
    Abstract: The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or sequence of the oligomer. In a preferred embodiment of the present invention the identifier tag is a microchip that is pre-encoded or encodable with information that is related back to a detector when the identifier tag is pulsed with electromagnetic radiation.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: April 3, 2007
    Assignee: Nexus Biosystems, Inc.
    Inventor: John Cargill
  • Patent number: RE39571
    Abstract: The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or sequence of the oligomer. In a preferred embodiment of the present invention the identifier tag is a microchip that is pre-encoded or encodable with information that is related back to a detector when the identifier tag is pulsed with electromagnetic radiation.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: April 17, 2007
    Assignee: Nexus Biosystems, Inc.
    Inventor: John Cargill
  • Patent number: RE39606
    Abstract: The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or sequence of the oligomer. In a preferred embodiment of the present invention the identifier tag is a microchip that is pre-encoded or encodable with information that is related back to a detector when the identifier tag is pulsed with electromagnetic radiation.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: May 1, 2007
    Assignee: Nexus Biosystems, Inc.
    Inventor: John Cargill
  • Patent number: RE47103
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 30, 2018
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Patent number: RE47131
    Abstract: The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: November 20, 2018
    Assignee: Therapeutic Human Polyclonals, Inc.
    Inventors: Josef Platzer, Roland Buelow, Wim van Schooten
  • Patent number: RE47245
    Abstract: This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and/or can be used to modulate the immune system of a subject.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 19, 2019
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, J. Kenneth Hoober
  • Patent number: RE47320
    Abstract: Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 26, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert, Susan M. Freier
  • Patent number: RE47672
    Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: October 29, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
  • Patent number: RE47691
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 5, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Patent number: RE47751
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 3, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Patent number: RE47768
    Abstract: The present invention relates to virus growth media that improve the yield of alpha-herpesviruses (e.g., HSV-2) grown in cell cultures. The growth media of the invention include two additives, a disaccharide and a lipid mixture, that can be added to serum-free or serum-enriched growth media to improve the efficiency of virus production. The invention further provides methods of producing alpha-herpesviruses (e.g., HSV-2) in such growth media.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: December 17, 2019
    Assignee: Sanofi Pasteur Biologics LLC
    Inventors: Simon Delagrave, Rachid Oubelaid, John Hamberger
  • Patent number: RE47769
    Abstract: Antisense molecules capable of binding to a selected target site in the dystrophin gene to induce exon skipping are described.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 17, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Patent number: RE47770
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: December 17, 2019
    Assignee: Merus N.V.
    Inventors: Patricius H. C. Van Berkel, Ronald Hendrik Brus, Ton Logtenberg, Abraham Bout
  • Patent number: RE47860
    Abstract: The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: February 18, 2020
    Assignee: Novartis AG
    Inventors: David Jenkins, Ming Lei, Andreas Loew, Li Zhou
  • Patent number: RE47982
    Abstract: The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. 2A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: May 12, 2020
    Assignee: Queen Mary & Westfield College, University of London
    Inventors: Fulvio D'Acquisto, Mauro Perretti
  • Patent number: RE48023
    Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: June 2, 2020
    Assignee: EYEGENE INC.
    Inventors: Doo-Sik Kim, Yang-Je Cho, Won-Il Yoo, Oh-Woong Kwon, Jin-Wook Jang, Hyeong-Joon Lim, Soo-Mee Kwon
  • Patent number: RE48137
    Abstract: Vaccine formulations effective against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) are disclosed, as well as methods of using the vaccine formulations in the treatment and prevention of Staphylococcus aureus infections in a subject.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 4, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Mark Shirtliff, Janette Harro, Jeffrey Leid
  • Patent number: RE48389
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: January 12, 2021
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Patent number: RE48404
    Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: January 26, 2021
    Assignee: Helixmith Co., Ltd
    Inventors: Jong-Mook Kim, Woong Hahn, Eun-Jin Park